Ergotamine has been used in clinical practice for the acute treatment of mi
graine for over 50 years, but there has been little agreement on its place
in clinical practice. An expert group from Europe reviewed the pre-clinical
and clinical data on ergotamine as it relates to the treatment of migraine
. From this review, specific suggestions for the patient groups and appropr
iate use of ergotamine have been agreed. In essence, ergotamine, from a med
ical perspective, is the drug of choice in a limited number of migraine suf
ferers who have infrequent or long duration headaches and are likely to com
ply with dosing restrictions. For most migraine sufferers requiring a speci
fic antimigraine treatment, a triptan is generally a better option from bot
h an efficacy and side-effect perspective.